Fiserv remains a 'buy' despite a 75% share price collapse, with recovery expected to be a multiyear process. Click here to ...
Medpace's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results